Comparisons of Placebo Effect of Hypoglycemic Drugs Between Asian and Caucasian Type 2 Diabetes Patients

Xiaoling Cai,Lingli Zhou,Wenjia Yang,Xueyao Han,Linong Ji

DOI: https://doi.org/10.1016/s0168-8227(16)31455-3

IF: 8.18

2016-01-01

Diabetes Research and Clinical Practice

Abstract:Objective To evaluate the placebo effect of hypoglycemic treatment in Chinese type 2 diabetes patients.Methods The MEDLINE,EMBASE,CENTRAL databases were searched and qualified studies were included.All the studies were double blind,placebo-controlled randomized trials in Chinese type 2 diabetes patients; patients age≥18 years; duration of follow-up study ≥12 weeks with the efficacy evaluated by changes in glycated hemoglobin A1c (HbA1c)or fasting plasma glucose (FPG)from baseline in groups.References were collected until Dec.2013.All statistical analyses were performed with the Review Manager statistical software package (Version 5.1).The Meta-analysis was performed by computing the weighted mean difference (WMD)for change from baseline to study endpoint.Results Totally 14 qualified studies were included.In terms of HbA1c change,treatment with placebo led to a significant HbA1c reduction from baseline(WMD,-0.33％ ; 95％CI:-0.41％ to-0.25％).In terms of FPG,treatment with placebo led to a non-significant reduction from baseline (WMD,-0.04 mmol/L; 95％ CI:-0.40 to 0.32 mmol/L).In terms of postprandial glucose(PPG),treatment with placebo led to a non-significant change from baseline (WMD,-0.32 mmol/L; 95％ CI:-0.87 to 0.22 mmol/L).Moreover,treatment with placebo led to a non-significant weight change from baseline(WMD,-0.44 kg;95％CI:-0.94 to 0.05 kg).Conclusion This Meta-analysis provided comprehensive clinical evidence on the placebo effect of hypoglycemic treatment in Chinese type 2 diabetes patients.Treatment with placebo led to a significant HbA1c reduction from baseline of 0.33％,but non-significant FPG,PPG or weight reduction from baseline.